1. Is there a reason for concern or is it just hype? – A systematic literature review of the clinical consequences of switching from originator biologics to biosimilars
- Author
-
Catalin Codreanu, Dinko Vitezić, CP Prins, Marcell Csanádi, András Inotai, and Zoltán Kaló
- Subjects
BIOMEDICINE AND HEALTHCARE. Clinical Medical Sciences ,medicine.medical_specialty ,Databases, Factual ,biosimilar ,immunogenicity ,patient access ,risk ,societal benefit ,substitution ,switch ,Clinical Biochemistry ,Alternative medicine ,BIOMEDICINE AND HEALTHCARE. Basic Medical Sciences. Pharmacology ,Biologic treatment ,Pharmacology ,Red-Cell Aplasia, Pure ,03 medical and health sciences ,0302 clinical medicine ,Neoplasms ,Rheumatic Diseases ,Drug Discovery ,medicine ,Humans ,Intensive care medicine ,Biosimilar Pharmaceuticals ,030203 arthritis & rheumatology ,business.industry ,BIOMEDICINA I ZDRAVSTVO. Kliničke medicinske znanosti ,Anemia ,Biosimilar ,Health Care Costs ,BIOMEDICINA I ZDRAVSTVO. Temeljne medicinske znanosti. Farmakologija ,Inflammatory Bowel Diseases ,Epoetin Alfa ,Clinical trial ,Systematic review ,030220 oncology & carcinogenesis ,Kidney Failure, Chronic ,business - Abstract
Introduction: While prescribing biosimilars to patients naive to a biologic treatment is a well- accepted practice, switching clinically stable patients from an originator to a biosimilar is an issue for clinicians. Well designed clinical trials and real-world data which study the consequences of switching from an originator biologic treatment to its biosimilar alternative are limited, especially for monoclonal antibodies. Areas covered: A systematic literature review was conducted on PubMed to identify evidence of the consequences of switching from original biologics to biosimilars. References of included papers were also scrutinized. After a title-, abstract- and full text screening, out of the 153 original hits and 77 additional ones from screening the references, 58 papers (12 empirical papers, 5 systematic reviews and 41 non-empirical papers) were included. Expert opinion: Preventing patients on biologic medicines from switching to biosimilars due to anticipated risks seems to be disproportional compared to the expected cost savings and/or improved patient access. Indeed, it is the opinion of the authors that the concern of switching to biosimilars is overhyped.
- Published
- 2017
- Full Text
- View/download PDF